A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

NCT00510718 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Hormone Refractory Prostate Cancer

Interventions

DRUG: MDV3100

Sponsor

Pfizer

Collaborators

[object Object]
[object Object]